Human Umbilical Cord-derived Mesenchymal Stem Cells (Vcanbio Cell & Gene)

脐带间充质干细胞疗法（中源协和细胞基因工程）

Report date: 2026/04/27 20:02:09

Base Information

Drug NameHuman Umbilical Cord-derived Mesenchymal Stem Cells (Vcanbio Cell & Gene)
Drug Alias NameHuman Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection (Vcanbio Cell & Gene)人脐带源间充质干/基质细胞注射液VUM02VUM-02hUCT-MSC +[7] 
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetic peripheral neuropathyCoronavirus Disease 2019 (COVID-19)Decompensated Liver Cirrhosis +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesVcanbio Cell & Gene Engineering Corp Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhongyuan Pharmaceutical Co LtdWuhan Optics Valley Zhongyuan Pharmaceutical Co LtdVcanbio Cell & Gene Engineering Corp Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic peripheral neuropathyCoronavirus Disease 2019 (COVID-19)Decompensated Liver Cirrhosis +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A